AI-driven drug development is transforming the life sciences industry ... but it also introduces critical vendor risks that many companies aren’t fully prepared to manage, reports Shachi Rai Gupta (pictured), is a global business and digital strategy leader and Vice President of Strategy at ORO Labs.
As AI adoption expands in pharmaceutical R&D, procurement teams face increasing challenges in terms of ensuring data privacy, evaluating AI vendors for ethical governance and keeping pace with evolving regulatory requirements.
Without a structured approach, organisations risk working with vendors whose data practices, bias mitigation strategies or transparency measures don’t meet industry standards.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.